Tillkännagivande • Aug 14

Ovid Therapeutics Reports Pipeline and Business Updates

Ovid Therapeutics Inc. announced that OV4071 advancing in Phase 1 study: Ovid continues to progress OV4071 through an ongoing Phase 1 study in healthy volunteers. The Phase 1 study is intended to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of this first-ever oral direct potassium-chloride cotransporter 2 (KCC2) activator. Data from the study are expected to support initiation of a Phase 2 proof-of-concept study in acute schizophrenia in 2027 and provide insights into future development across additional high-value central nervous system (CNS) indications. A growing body of pharmacodynamic and translational data demonstrates OV4071’s ability to restore excitatory/inhibitory (E/I) balance across more than 40 disease models, including psychosis, cognition and behavioral dysfunction with results meeting or exceeding marketed traditional antipsychotics. In preclinical studies, OV4071 also demonstrated favorable properties and no evidence of sedation. OV4071 is supported by a translational biomarker strategy designed to help guide and de-risk clinical development. Ketamine challenge study: Building on the encouraging Phase 1 results thus far and as a part of the clinical development plan, Ovid intends to initiate a ketamine challenge study of OV4071 in the second half of 2026 to further characterize potential pharmacodynamic effects and proof-of-mechanism using electrophysiology and biomarkers. The study is designed to reproduce biological and neurotransmitter surges of glutamate and dopamine in a healthy volunteer to assess key biomarkers relevant to schizophrenia and other potential indications. KCC2 portfolio expansion; advancing next-generation compounds to support broad CNS therapeutic potential: Ovid has a discovery engine focused on identifying novel KCC2 direct activator molecules that are amenable for oral and injectable administration and moving them into IND-enabling studies. OV329 next-generation GABA-AT inhibitor: Phase 2 initiated with proof-of-concept studies underway, supporting continued development across multiple seizure disorders. Ovid continues to advance OV329, its next-generation 4-aminobutyrate aminotransferase (GABA-AT) inhibitor, through proof-of-concept studies designed to establish the program's clinical potential across multiple seizure disorders. OV329 acts as a GABA-AT inhibitor and this represents a mechanism of action that has been previously validated in multiple seizure disorders. Building upon robust cortical inhibition that was established in human healthy volunteers, the Company is expanding development into multiple indications, including treatment-resistant focal onset seizures (FOS), tuberous sclerosis complex (TSC)-associated seizures and infantile spasms (IS). Initiated Phase 2 randomized, placebo-controlled study evaluating efficacy, safety and tolerability in treatment-resistant FOS:Ovid has received regulatory clearance across multiple regions and has initiated the dose-confirmatory study to evaluate seizure reduction efficacy, safety and tolerability of OV329 in people living with treatment-resistant FOS. This global study is designed with registrational-level rigor to potentially support multiple future seizure indications for OV329. The study is anticipated to be completed in the second half of 2027; Exploratory proof-of-mechanism photosensitivity study:Ovid has received regulatory clearances and has initiated a photo stimulation study to evaluate the anti-convulsant effect of multiple potential doses of OV329. The Company intends to test three doses of OV329, including 5, 7 and 9 milligrams, and anticipates results near year end 2026; Proof-of-concept studies in developmental epileptic encephalopathies (DEEs), TSC and IS:Ovid is in the process of initiating development programs for OV329 to assess proof of safety and anti-convulsant effect in TSC-associated seizures and IS using a weight-based pediatric formulation, which is independent from the adult fixed-dose tablets being tested in FOS. The Company expects to initiate a proof-of-concept safety and signal-finding study in the fourth quarter of 2026 to evaluate OV329 in patients with TSC-associated seizures. This study will help inform the dosing strategy for a subsequent study in IS, which is anticipated to commence in 2027. GABA-AT inhibition has previously been established as an effective mechanism of action in these DEEs, and OV329 is designed to be a GABA-AT inhibitor with a favorable safety, tolerability and efficacy profile.

Tillkännagivande • Jul 23

Ovid Therapeutics Inc. Expands Scientific Advisory Board

Ovid Therapeutics Inc. announced it has significantly expanded its SAB with the appointment of renowned neurologists, neuroscientists, and epileptologists. Working together with the SAB, Ovid looks to optimize its research, translation and clinical development plans. Members of the Ovid Therapeutics Scientific Advisory Board: Robert Langer is the chair of Ovid’s Scientific and Clinical Advisory Board. Dr. Langer is one of 10 Institute Professors at MIT and has written over 1,500 scholarly articles. He is also the most cited engineer in history (h-index 286, with over 338,000 citations according to Google Scholar). He has served as the chair of the U.S. Food and Drug Administration’s Science Board, and has been recognized with over 220 awards, including the United States National Medals of both Science and Technology and Innovation. Dr. Langer was named as one of the 20 most important people in biotechnology by Discover magazine and one of 15 innovators who will reinvent the company's future by Forbes. TIME and CNN named him as one of the most important people in America and one of the 18 top people in science or medicine in America. He was also recognized as one of the world’s 25 most important individuals in biotechnology by Forbes and by BioWorld. Dr. Langer holds 35 honorary doctorate degrees and has been elected to the National Academies of Medicine, Engineering, Sciences and Inventors. Imad Najm, M.D., is the Vice Chair for Strategy and Development at the Cleveland Clinic Neurological Institute and Director of the Cleveland Clinic Epilepsy Center (2006-present). He is an Adjunct Professor in the Department of Biomedical Engineering at Case Western Reserve University and the Department of Neurobiology at Kent State University. Dr. Najm also has served as the Co-Director of Basic Sciences and Neurosciences at Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Head of Adult Epilepsy and Director of the Epilepsy and Clinical Neurophysiology fellowship at Cleveland Clinic. His research over the last 34 years has been funded by the National Institutes of Health (NIH), the U.S. Department of Defense, the Epilepsy Foundation, and multiple philanthropic donations. He has published 275 peer-reviewed papers in multiple journals, authored or co-authored many book chapters and edited two textbooks. He has lectured on epilepsy in more than 30 countries and organized international symposia, courses and workshops in more than 15 countries. His main areas of research interest include the mechanisms of disease (epileptogenicity/epileptogenesis), clinical and imaging correlates, and surgical management of focal cortical dysplasia. He has been teaching Basic Neurosciences at Cleveland Clinic Lerner College of Medicine since 2005. He has mentored and co-mentored more than 300 epilepsy fellows and graduate students. Dr. Najm designed and co-directed the Neuroscience Curriculum at Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. Dr. Najm received his M.D. from Saint Joseph University in Beirut, Lebanon. He had post-graduate training in neurobiology at the University of Southern California and the University of California, Irvine. He also did post-graduate training in neurology, epilepsy, and clinical neurophysiology at Cleveland Clinic. Raman Sankar, M.D., Ph.D., is the Emeritus Chief of Pediatric Neurology at UCLA Health. He is an elected Fellow of the American Academy of Neurology and the American Epilepsy Society, and a member of the American Pediatric Society, the Child Neurology Society and the Society for Neuroscience. He has served on several editorial boards of journals dedicated to epilepsy research and has also served on several NINDS-NIH review committees. He is a recipient of the Founders Award of the American Epilepsy Society, the highest honor conferred by the Society in recognition of outstanding lifetime achievement in the field of epilepsy. Board certified in neurology with special qualification in child neurology, he has dedicated over three decades to advancing research and clinical practices in epilepsy and child neurology. Dr. Sankar holds an M.D. from Tulane University and a Ph.D. in medicinal chemistry from the University of Washington. Jamie Maguire, Ph.D., is Professor of Neuroscience at Tufts University School of Medicine and was named the Kenneth and JoAnn G. Wellner Professor in Neuroscience in 2019. Dr. Maguire is a member of the Graduate Biomedical Sciences Pharmacology and Neuroscience programs. She is the Director of the Building Diversity in Biomedical Sciences (BDBS) program and has a strong commitment to increasing diversity, equity, and inclusion in STEM and beyond. Her current research focuses on a systems physiology approach to the study of neurological and neuropsychiatric diseases, focusing on epilepsy and mood disorders, which has led to successful clinical trials for postpartum depression treatments. She received a BS in neuroscience and BA in the history of art and architecture from the University of Pittsburgh and her Ph.D. in neuroscience from George Washington Univ ersity. Dr. Maguire trained as a postdoctoral fellow at UCLA investigating the ability of steroid hormones and neurosteroids to modulate GABAergic inhibition and their impact on mood disorders and epilepsy. Jeffrey Noebels, M.D., Ph.D., is the Cullen Trust for Health Care Endowed Chair in Neurogenetics, and Professor of Neurology, Neuroscience, and Molecular and Human Genetics at Baylor College of Medicine, where he directs the Blue Bird Circle Developmental Neurogenetics Laboratory. Dr. Noebels is a past president of the American Epilepsy Society and fellow of the American Association for the Advancement of Science. Dr. Noebels’ research involves understanding how single genes regulate neuronal excitability and network synchronization within the central nervous system. His lab's recent work on mouse models of Alzheimer’s Disease and glioblastoma-related epilepsy has provided pioneering insights into the role of hyperexcitability in cognitive decline and umorigenesis. He received a BA from Reed College, an M.D. from Yale University School of Medicine, and his Ph.D. from Stanford University. Dr. Noebels conducted his neurology residency at Massachusetts General Hospital, and a post-doctoral fellowship at Harvard University. Board certified in neurology by the American Board of Psychiatry and Neurology, his research interests include gene control of neuronal excitability within the developing central nervous system, inherited neurological diseases, and epilepsy.

Biotechs Tillväxt i branschen	17.04%
Intäkternas tillväxttakt	-89.56%
Avkastning på eget kapital	-16.43%
Nettomarginal	-2,177.95%
Senaste uppdateringen av resultatet	30 Jun 2026

Datum	Intäkter	Intäkter	G+A Kostnader	FoU-kostnader
30 Jun 26	2	-34	26	34
31 Mar 26	7	-24	25	30
31 Dec 25	7	-17	24	26
30 Sep 25	7	-36	21	25
30 Jun 25	7	-38	22	27
31 Mar 25	1	-24	22	31
31 Dec 24	1	-26	24	35
30 Sep 24	1	-32	27	40
30 Jun 24	1	-29	26	37
31 Mar 24	0	-50	28	32
31 Dec 23	0	-51	30	28
30 Sep 23	0	-49	31	24
30 Jun 23	0	-49	32	25
31 Mar 23	0	-51	31	23
31 Dec 22	2	-54	32	25
30 Sep 22	1	-68	33	37
30 Jun 22	1	-66	32	36
31 Mar 22	1	-67	32	39
31 Dec 21	208	120	37	47
30 Sep 21	214	123	39	46
30 Jun 21	221	117	40	57
31 Mar 21	221	110	41	65
31 Dec 20	13	-81	31	63
30 Sep 20	7	-76	25	59
30 Jun 20	0	-76	23	54
31 Mar 20	0	-67	20	47
31 Dec 19	0	-60	19	42
30 Sep 19	0	-56	19	39
30 Jun 19	0	-53	18	36
31 Mar 19	0	-53	19	35
31 Dec 18	0	-52	19	34
30 Sep 18	0	-50	19	32
30 Jun 18	0	-46	18	29
31 Mar 18	0	-44	17	27
31 Dec 17	0	-65	15	50
30 Sep 17	0	-61	14	47
30 Jun 17	0	-58	14	44
31 Mar 17	0	-53	13	40
31 Dec 16	0	-22	13	10
30 Sep 16	0	-18	12	2

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/08/21 22:26
Aktiekurs vid dagens slut	2026/08/21 00:00
Intäkter	2026/06/30
Årlig intjäning	2025/12/31

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

Analytiker	Institution
Kalpit Patel	B. Riley Securities, Inc.
Madison Wynne El-Saadi	B. Riley Securities, Inc.
Thomas Shrader	BTIG

Ovid Therapeutics Tidigare resultatutveckling

Tidigare kriterier kontrolleras 0/6

Viktig information

Senaste uppdateringar av tidigare prestationer

Second quarter 2026 earnings released: US$0.076 loss per share (vs US$0.065 loss in 2Q 2025)

First quarter 2026 earnings released: US$0.13 loss per share (vs US$0.14 loss in 1Q 2025)

Full year 2025 earnings: EPS and revenues exceed analyst expectations

Third quarter 2025 earnings: EPS and revenues miss analyst expectations

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

New major risk - Revenue and earnings growth

New minor risk - Revenue size

Second quarter 2026 earnings released: US$0.076 loss per share (vs US$0.065 loss in 2Q 2025)

Ovid Therapeutics Reports Pipeline and Business Updates

OVID: Phase 1 Psychosis Program Will Drive Future Repricing Potential

Price target increased by 8.5% to US$5.69

Ovid Therapeutics Inc. Announces CFO Changes

Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth

OVID: Index Inclusion And New Psychosis Indications Will Support Bullish Outlook

Ovid Therapeutics Inc Announces Appointment of Anna Greka to Board of Directors and Committee Changes, Effective June 15, 2026

Consensus revenue estimates decrease by 39%, EPS upgraded

First quarter 2026 earnings released: US$0.13 loss per share (vs US$0.14 loss in 1Q 2025)

Ovid Therapeutics Inc., Annual General Meeting, Jun 10, 2026

Long Term Epilepsy And Psychosis Pipeline Will Reshape Prospects For This Undervalued Biotech

New major risk - Revenue and earnings growth

Price target increased by 7.9% to US$4.45

Full year 2025 earnings: EPS and revenues exceed analyst expectations

Expanding Neurology Pipeline And Extended Cash Runway Will Support Powerful Long Term Upside Potential

Ovid Therapeutics Inc. announced that it expects to receive $59.99992 million in funding from a group of investors

Now 22% overvalued

Now 29% overvalued after recent price rise

New major risk - Shareholder dilution

New major risk - Share price stability

Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (Kcc2), Ov350 Intravenous (Iv)

Ovid Therapeutics Inc. Appoints Petra Kaufmann as Chief Medical Officer

Third quarter 2025 earnings: EPS and revenues miss analyst expectations

Ovid Therapeutics Inc. Announces Board Changes

Price target increased by 13% to US$3.85

Ovid Therapeutics Inc. announced that it has received $80.8108 million in funding from Janus Henderson Group plc, RA Capital Management, L.P., Blue Owl Healthcare Opportunities, ADAR1 Capital Management, LLC, Affinity Asset Advisors, LLC

Ovid Therapeutics Inc. Announces Positive Topline Results for the Next-Generation Gababatrin (Vg) Inhibitor, OV329

Price target decreased by 11% to US$2.85

Ovid Therapeutics: OV329 Promising For Neuronal Excitability In Neurological Disorders

Consensus revenue estimates increase by 2,024%

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

Price target decreased by 10% to US$2.88

Consensus revenue estimates increase by 22%

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Ovid Therapeutics Inc., Annual General Meeting, Jul 09, 2025

New minor risk - Share price stability

Consensus revenue estimates decrease by 16%

Price target decreased by 15% to US$2.88

Consensus revenue estimates decrease by 30%, EPS upgraded

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Ovid Therapeutics Inc. Appoints Stelios Papadopoulos to Its Board of Directors and Member of Audit and Compensation Committees

Ovid Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Minimum Closing Bid Price

High number of new and inexperienced directors

Consensus revenue estimates increase by 45%, EPS downgraded

New major risk - Financial position

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new and inexperienced directors

Ovid Therapeutics Appoints Dr. Amanda Banks, as Chief Development Officer

Ovid Therapeutics Inc. Expands Scientific Advisory Board

Ovid Therapeutics Inc. Announces That eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures

Ovid Therapeutics Inc.(NasdaqGS:OVID) dropped from Russell Small Cap Comp Value Index

Ovid Therapeutics Inc. and Graviton Bioscience Corporation Announce Topline Data from A Phase 1 Clinical Trial Studying OV888/GV101 Capsule

Consensus revenue estimates decrease by 87%, EPS upgraded

Consensus revenue estimates fall by 80%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Ovid Therapeutics Inc., Annual General Meeting, Jun 06, 2024

Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024

President recently bought US$50k worth of stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Consensus revenue estimates increase by 1,902%

We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth

Consensus revenue estimates increase by 51%

Price target increased by 20% to US$6.00

Consensus revenue estimates increase by 48%